Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SARCLISA vs BENLYSTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
Treatment of multiple myeloma in combination with pomalidomide and dexamethasone in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor,Treatment of multiple myeloma in combination with carfilzomib and dexamethasone in adults with relapsed or refractory multiple myeloma after 1-3 prior lines of therapy
Systemic lupus erythematosus (SLE) in patients with active, autoantibody-positive disease receiving standard therapy,Lupus nephritis (in combination with standard therapy)
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Isatuximab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via catabolic pathways. Not metabolized by CYP450 enzymes.
Belimumab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; clearance is thought to occur via proteolytic degradation.
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
~70% bound to plasma proteins (primarily albumin and beta-2 glycoprotein I/apoferritin).
Approximately 65–70% bound to plasma proteins, primarily immunoglobulins and albumin.
Vd: 0.09 L/kg (approx. 6 L), consistent with limited extravascular distribution.
Vd ~ 0.19 L/kg (approximately 13.5 L for a 70 kg adult), indicating limited distribution primarily to the vascular space.
IV only; bioavailability 100% by IV route. Not administered orally.
SC: ~82% relative to IV; IV: 100%.
No dose adjustment required for renal impairment (Cr Cl ≥15 m L/min). Not studied in end-stage renal disease (Cr Cl <15 m L/min) or dialysis; use caution.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD. Use caution and consider benefit-risk.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dedicated studies; however, belimumab is not metabolized by the liver. No dose adjustment recommended based on Child-Pugh class.
Safety and efficacy not established in pediatric patients. No recommended dose.
In pediatric patients (>=5 years): IV: 10 mg/kg IV at 2-week intervals for first 3 doses, then 10 mg/kg IV every 4 weeks. SC: 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses). Not approved for children <5 years.
No specific dose adjustment required. Consider comorbidities and renal function, but pharmacokinetics are similar to younger adults.
No specific dose adjustment; select with caution due to greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy. Monitor for infections and adverse reactions.
No FDA black box warning.
No FDA black box warning.
Infusion-related reactions (may require premedication and monitoring),Neutropenia (monitor complete blood counts),Thrombocytopenia,Second primary malignancies,Interference with blood cross-matching (due to CD38 binding),Embryofetal toxicity
Hypersensitivity reactions including anaphylaxis,Infusion reactions,Increased risk of serious infections, including tuberculosis and opportunistic infections,Malignancy risk (potential),Hypogammaglobulinemia,Depression and suicidality
None known.
None known; caution in patients with severe active infections.
No specific food interactions. Avoid grapefruit juice if taking concurrent CYP3A4 substrates (e.g., pomalidomide) due to potential interaction. Maintain adequate hydration.
No known food interactions. May be taken without regard to meals.
First trimester: Ig G1 monoclonal antibodies cross placenta minimally; limited human data, but based on mechanism (CD38 inhibition), potential fetal hematologic effects. Second/third trimesters: Increased placental transfer; risk of fetal cytopenias and immune suppression.
First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell depletion as Ig G crosses placenta after 13 weeks gestation. Third trimester: Ig G actively transported across placenta; risk of neonatal immunosuppression (e.g., prolonged B-cell depletion, increased infection risk).
No data on human milk excretion; M/P ratio unknown. Human Ig G enters breast milk, but degradation in infant GI tract likely limits absorption. Weigh benefits of breastfeeding against potential infant exposure.
No human data on belimumab in breast milk. Belimumab is a large monoclonal antibody likely present in milk at low concentrations. M/P ratio unknown. Developmental benefits of breastfeeding should be weighed against potential infant exposure and risk of immunosuppression.
No PK studies in pregnancy; dose adjustments not established. Isatuximab clearance may increase due to expanded plasma volume and altered Fc Rn activity, but no data to recommend specific changes. Use only if benefit outweighs risk.
No dose adjustment recommended based on pregnancy pharmacokinetic changes. However, caution advised due to limited data. Dose may need adjustment if concomitant immunosuppressants used.
SARCLISA (isatuximab) is an anti-CD38 monoclonal antibody for multiple myeloma. Premedicate with acetaminophen, H1 and H2 antagonists, and corticosteroids before infusion to reduce infusion-related reactions. Administer pomalidomide and dexamethasone concurrently as per protocol. Monitor for neutropenia, infusion reactions, and second primary malignancies. Do not substitute for other anti-CD38 antibodies.
BENLYSTA (belimumab) is a BLy S-specific inhibitor for adjunctive therapy in active systemic lupus erythematosus (SLE). Monitor for hypersensitivity reactions during infusion. Do not administer with live vaccines. Contraindicated in severe active lupus nephritis or severe active CNS lupus. Renal function monitoring required due to potential for progressive multifocal leukoencephalopathy (PML) risk.
Infusion reactions: symptoms like fever, chills, rash, or difficulty breathing may occur during or after infusion; seek immediate medical attention.,Blood cell counts: this drug can decrease white blood cells, red blood cells, and platelets; report signs of infection, anemia, or bleeding.,Fetal harm: effective contraception required during and for 5 months after treatment; do not breastfeed.,Vaccinations: avoid live vaccines during treatment.,Laboratory interference: isatuximab may interfere with blood compatibility testing; inform all healthcare providers of treatment.
Report any signs of allergic reaction during or after infusion immediately.,Avoid live vaccines during treatment and for at least 30 days after stopping.,Inform doctor of any new or worsening neurological symptoms.,Use effective contraception during therapy and for 4 months after last dose.,Do not stop or change dose without consulting your rheumatologist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SARCLISA vs BENLYSTA, answered by our medical review team.
SARCLISA is a Monoclonal Antibody, Antineoplastic that works by Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.. BENLYSTA is a Monoclonal Antibody that works by Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SARCLISA and BENLYSTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SARCLISA is: 10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.. The standard adult dose of BENLYSTA is: 10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SARCLISA and BENLYSTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SARCLISA is classified as Category C. First trimester: IgG1 monoclonal antibodies cross placenta minimally; limited human data, but based on mechanism (CD38 inhibition), potential fetal hematologic effects. Second/thir. BENLYSTA is classified as Category C. First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell dep. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.